12:00 AM
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Folotyn pralatrexate regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-4 to recommend accelerated approval of Folotyn pralatrexate from Allos to treat relapsed or refractory peripheral T cell lymphoma (PTCL). The committee felt...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >